HC Wainwright Reaffirms Buy Rating for Harrow (NASDAQ:HROW)

HC Wainwright restated their buy rating on shares of Harrow (NASDAQ:HROW - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $57.00 target price on the stock. HC Wainwright also issued estimates for Harrow's Q4 2024 earnings at $0.16 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley dropped their price objective on Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th.

Harrow Trading Up 1.1 %

HROW traded up $0.32 during trading hours on Tuesday, reaching $28.41. 625,226 shares of the company's stock traded hands, compared to its average volume of 492,194. The firm has a 50-day moving average price of $29.51 and a 200 day moving average price of $38.39. Harrow has a 52-week low of $9.86 and a 52-week high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm has a market capitalization of $1.01 billion, a PE ratio of -30.22 and a beta of 0.69.

Institutional Investors Weigh In On Harrow

Hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new stake in shares of Harrow in the 3rd quarter worth $29,000. GF Fund Management CO. LTD. purchased a new stake in shares of Harrow in the 4th quarter worth $25,000. Tower Research Capital LLC TRC lifted its holdings in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of Harrow in the 4th quarter worth $78,000. Finally, AlphaQuest LLC lifted its holdings in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after buying an additional 2,889 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.